Question

12. What dose-limiting adverse effect is associated with bleomycin?

A. Bronchospasm. B. Pleural Effusion. C. Pulmonary Fibrosis. D. Alveolar Hemorrhage.

13. Containers used for the disposal of medication-contaminated items are:

A. Colored in red and rigid. B. Stored with hospital waste. C. Marked with the contents. D. Labeled as infectious waste.

14. A patient receiving nivolumab has a folow-up CT-scan 12 weeks into therapy, which shows a very slight increase in size of lung tumors. In the absence of any other significant changes in condition, what is the expected treatment for the patient?

A. Increase the dose. B. Discontinue the agent. C. Continue therapy. D. Change the treatment medication.

Answer 1

12. What dose-limiting adverse effect is associated with bleomycin?

Ans : C. Pulmonary Fibrosis.

13. Containers used for the disposal of medication-contaminated items are:

Ans :B. Marked with the contents

14. A patient receiving nivolumab has a folow-up CT-scan 12 weeks into therapy, which shows a very slight increase in size of lung tumors. In the absence of any other significant changes in condition, what is the expected treatment for the patient?

Ans :C. continue therapy

The patient was administered nivolumab as fourth‐line therapy; however, after three cycles, the tumor increased in size. After six cycles of nivolumab, disease progression was evident.